CD24 and breast carcinoma: An in-depth analysis of the competitive endogenous RNA (ceRNA) network between CD24-high and CD24-low tumor samples of breast carcinoma, using transcriptome profiles from the TCGA database, identified the CD24-associated ceRNA RP1-228H13.5/miR-135a-5p/BEND3 and SIM2 axis as potential therapeutic targets and predictors for breast invasive carcinoma (BRCA) diagnosis and prognosis [24].